(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2009 (11.09.2009)

PCT

(10) International Publication Number
WO 2009/109908 A8

(51) **International Patent Classification**:
A61K 39/395 (2006.01) *A61P 25/00* (2006.01)
C07K 16/26 (2006.01) *A61P 29/00* (2006.01)

(21) **International Application Number**:
PCT/IB2009/050849

(22) **International Filing Date**:
3 March 2009 (03.03.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/033,568 4 March 2008 (04.03.2008) US

(71) **Applicant** *(for all designated States except US)*: **PFIZER LIMITED** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **CORRADINI, Laura** [IT/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **MACHIN, Ian** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **POULSEN, Kristian, Todd** [US/US]; Rinat Laboratories, Biotherapeutics and Bioinnovation Center Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080 (US). **SHELTON, David, Louis** [US/US]; Rinat Laboratories, Biotherapeutics and Bioinnovation Center Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080 (US). **ZELLER, Joerg** [DE/US]; Rinat Laboratories, Biotherapeutics and Bioinnovation Center Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080 (US).

(74) **Agent**: **DROUIN, Stephane**; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version**:
19 August 2010

(15) **Information about Corrections**:
see Notice of 19 August 2010

Previous Correction:
see Notice of 29 October 2009

(54) **Title**: METHODS OF TREATING INFLAMMATORY PAIN

(57) **Abstract**: Methods of Treating Inflammatory Pain The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody.

WO 2009/109908 A8